Business Context and Reporting Period
This Form 8-K was filed by Werewolf Therapeutics, Inc. on December 18, 2025. The report details a pipeline update regarding the Company's INDUKINE programs and outlines business priorities for 2026. Werewolf is an emerging growth company focused on developing T-cell engager therapeutics, specifically utilizing its proprietary INDUCER platform to improve therapeutic indices in oncology.
Key Financial Metrics
The filing text does not provide specific financial statements, revenue, profit, cash flow, margins, debt, or liquidity figures. The report explicitly states that additional funding will be required to initiate further development, including registration-enabling trials for WTX-124 and sequential administration studies for WTX-330.
Material Changes and Clinical Data
The filing highlights significant clinical progress and data updates as of late October 2025:
- WTX-124 (Phase 1/1b):
- Monotherapy objective response rate (ORR) of 21% in heavily pretreated advanced/metastatic cutaneous melanoma.
- ORR of 30% observed in melanoma patients with prior response to immunotherapy.
- Tumor regression seen in approximately 33% of tumors across multiple solid tumor indications.
- Safety profile showed no evidence of vascular leak syndrome; Grade 3/4 adverse events occurred in 25.5% and 1.9% of patients, respectively.
- FDA accepted 18 mg as the recommended dose and provided initial guidance for a monotherapy registration path in post-ICI melanoma.
- WTX-330 (Phase 1b/2):
- First twelve patients treated showed favorable tolerability and antitumor activity.
- Optimized manufacturing improved safety and pharmacokinetics; Cmax was 17-fold higher than published rhIL-12.
- One confirmed partial response in metastatic gall bladder cancer with a 45% reduction in tumor target lesions.
- Preclinical Pipeline:
- WTX-1011 (targeting STEAP1) and WTX-2022 (targeting CDH6) demonstrated robust silencing and anti-tumor activity in preclinical models.
- IND filings for these candidates are planned for mid-2027, pending funding.
Guidance, Outlook, and Risks
2026 Priorities and Timeline:
- Completion of the WTX-124 Phase 1/1b trial is expected in the first half of 2026, with an additional data update planned.
- An update from Part A of the WTX-330 Phase 1b/2 trial is also expected in the first half of 2026.
- The Company is actively seeking strategic partnerships for the further development of WTX-124 and WTX-330.
Risks and Contingencies:
- Funding Dependency: Continued development and registration trials are contingent upon securing additional capital.
- Forward-Looking Statements: The filing includes standard disclaimers regarding uncertainties in clinical trial results, regulatory approvals, and the ability to manage cash resources.
- Development Risks: Preliminary data may not be predictive of future results, and there are risks associated with the initiation and completion of preclinical and clinical studies.
Investor Verification Checklist
- Verify the Company's current cash runway and specific capital requirements for 2026 development milestones.
- Confirm the status of strategic partnership discussions for WTX-124 and WTX-330.
- Review the full FDA guidance received regarding the WTX-124 registration path in post-ICI melanoma.
- Monitor the timeline for the first-half 2026 data updates for both WTX-124 and WTX-330.
- Assess the progress of IND-enabling studies for WTX-1011 and WTX-2022 toward the mid-2027 filing target.